The Obesity ETF (SLIM) ETF Analysis
The Obesity ETF (SLIM) is a non-diversified equity ETF with $0.01 billion in assets under management and an expense ratio of 0.35%.
SLIM provides exposure to companies positioned to profit from servicing the obese, including those in biotechnology, pharmaceuticals, healthcare, medical devices, weight loss programs, supplements, and plus-sized apparel. The fund seeks to track the Solactive Obesity Index, offering a targeted investment in a specific health and consumer trend.
The Obesity ETF (SLIM) ETF — Price, Holdings & Analysis
ETF Overview
Risk Metrics
Expense Ratio
What does SLIM hold?
How Is the Fund Allocated?
| Sector | Weight |
|---|---|
| Healthcare | 91.9% |
| Consumer Defensive | 4.3% |
| Consumer Cyclical | 3.9% |
Dividend Yield
- Invesco QQQ Trust, Series 1 (QQQ) — 0.18% expense ratio
- State Street Technology Select Sector SPDR ETF (XLK) — 0.08% expense ratio
- State Street Energy Select Sector SPDR ETF (XLE) — 0.08% expense ratio
- State Street SPDR Dow Jones Industrial Average ETF Trust (DIA) — 0.16% expense ratio
- iShares Russell 2000 ETF (IWM) — 0.19% expense ratio
- State Street Financial Select Sector SPDR ETF (XLF) — 0.08% expense ratio
- iShares MSCI Emerging Markets ETF (EEM) — 0.72% expense ratio
- State Street SPDR S&P 500 ETF (SPY) — 0.09% expense ratio
Risk Metrics
- Beta: 0.70
Questions & Answers
What is SLIM and what does it track?
The Obesity ETF (SLIM) seeks to replicate the performance of the Solactive Obesity Index. This index is designed to track companies globally that are positioned to profit from servicing the obese population.
These companies include those involved in biotechnology, pharmaceuticals, healthcare, medical devices, weight loss programs, weight loss supplements, and plus-sized apparel.
What is the expense ratio for SLIM?
The expense ratio for SLIM is 0.35%. This means that for every $10,000 invested in the fund, $35 is deducted annually to cover operating expenses.
While it's difficult to determine a precise category average for such a niche thematic ETF, the expense ratio is comparable to other specialized equity ETFs. Investors should consider the expense ratio as a factor impacting the overall return of the fund over time.
What are the top holdings in SLIM?
SLIM's top holdings reflect its focus on companies involved in obesity-related products and services.
As of 2026-03-15, the top three holdings are Novo Nordisk A/S ADR (19.95%), a leading pharmaceutical company in diabetes and obesity care; DexCom Inc (13.38%), which specializes in continuous glucose monitoring systems; and Fresenius Medical Care AG & Co.
Is SLIM a good long-term investment?
Whether SLIM is a suitable long-term investment depends on an individual's investment goals and risk tolerance. The fund offers targeted exposure to a specific theme, which can lead to concentrated risk.
SLIM's performance will be influenced by the growth of the obesity-related market and the success of its constituent companies.
How does SLIM compare to similar ETFs?
SLIM is unique in its specific focus on companies profiting from the obesity market. While there aren't many directly comparable ETFs, some broader healthcare ETFs may have overlapping holdings.
SLIM's expense ratio of 0.35% is competitive within the thematic ETF space. With AUM of $0.01 billion, SLIM is a relatively small ETF, which can impact liquidity and trading costs.
Does SLIM pay dividends?
Yes, SLIM pays dividends. The current dividend yield for SLIM is 0.57%. This means that for every $100 invested in the fund, investors can expect to receive $0.57 in dividend payments annually.
The dividend yield may fluctuate based on the performance of the underlying holdings and the fund's distribution policy.